Less is as good as more in refractory melanoma

Nature Reviews Clinical Oncology

Volumn 11, Issue 9, 2014, Pages 502-

  Hutchinson, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IPILIMUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

BRAF GENE; CANCER GROWTH; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; GENE; HUMAN; LOW DRUG DOSE; MELANOMA; MULTICENTER STUDY (TOPIC); NOTE; OVERALL RESPONSE RATE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REFRACTORY ADVANCED STAGE MELANOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84906831693     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.132     Document Type: Note

References (1)

1. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase I trial. Lancet doi:10.1016/S0140-6736(14) 60958-2